Lawyers representing Luigi Mangione, the man accused of murdering UnitedHealthCare CEO Brian Thompson, have accused federal prosecutors of operating under a “profound conflict of interest,” pointing to Attorney General Pam Bondi’s prior work as a lobbyist for a firm representing UnitedHealth Group. The allegation was laid out in court filings this week as the defense intensifies efforts to block the death penalty.
Bondi previously worked as a lobbyist for Ballard Partners, a firm that has represented UnitedHealth Group. According to Mangione’s defense team, that relationship raises serious questions about the impartiality of the prosecution, particularly given Bondi’s decision to instruct federal prosecutors to seek capital punishment over what she described as a “premeditated, cold-blooded assassination” in late 2024.
The defense is now seeking detailed information about Bondi’s lobbying work, including whether she had direct involvement with UnitedHealth Group and whether she received any compensation linked to that representation. Lawyers argue that even the appearance of financial or professional ties between the attorney general and a company connected to the victim undermines the integrity of the case.
In their filing, Mangione’s attorneys said that “any criminal defendant, let alone one who the government is trying to kill, is due a criminal process that is untainted by the financial interests of his prosecutors.” They contend that the alleged conflict is especially troubling given the irreversible nature of the death penalty.
The filing comes after a series of legal setbacks for prosecutors. The defense has already succeeded in having terrorism-related charges against Mangione dismissed. Attorneys are now pushing to suppress additional evidence, arguing that it was obtained unlawfully, including items seized during what they describe as a warrantless search of Mangione’s backpack and statements he allegedly made before being informed of his Miranda rights.
Mangione, 27, is accused of killing Thompson in what authorities say was an act of targeted violence against a senior figure in the US health insurance industry. The case has drawn intense public attention and become a flashpoint in broader debates about justice, corporate power, and political influence.
Supporters of Mangione have framed the killing as an act of vigilante justice, citing widespread anger over insurance practices and healthcare fraud that they say have caused immense harm to ordinary Americans. Critics, however, argue that excusing the killing risks legitimizing political violence and encouraging copycat attacks.
As the legal battle unfolds, the case is increasingly seen as a test of whether the US justice system applies the same standards to all defendants, regardless of political connections or corporate influence. Whether the court will entertain the defense’s conflict-of-interest claims could have significant implications not only for Mangione’s fate, but for public trust in the prosecution itself.
